Last reviewed · How we verify
Lamictal TM
Lamictal TM is a Anticonvulsant / Mood stabilizer Small molecule drug developed by Central Mental Clinic for Outpatients of Baku City. It is currently FDA-approved for Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome), Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes).
Lamictal (lamotrigine) inhibits voltage-gated sodium channels and reduces glutamate release, stabilizing neuronal membranes and reducing excitatory neurotransmission.
Lamictal (lamotrigine) is an anticonvulsant primarily used for epilepsy and bipolar disorder. It has a unique mechanism of action and is being explored for schizophrenia, though a recent trial was terminated.
At a glance
| Generic name | Lamictal TM |
|---|---|
| Sponsor | Central Mental Clinic for Outpatients of Baku City |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | Voltage-gated sodium channels; glutamate release inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lamotrigine blocks sodium channels in a use-dependent manner, which stabilizes the resting membrane potential and reduces the frequency of action potentials. It also inhibits the release of glutamate, the primary excitatory neurotransmitter in the central nervous system. These mechanisms reduce neuronal hyperexcitability and are thought to underlie its anticonvulsant and mood-stabilizing effects.
Approved indications
- Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome)
- Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes)
Common side effects
- Rash (including Stevens-Johnson syndrome risk)
- Dizziness
- Ataxia
- Diplopia
- Headache
- Nausea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamictal TM CI brief — competitive landscape report
- Lamictal TM updates RSS · CI watch RSS
- Central Mental Clinic for Outpatients of Baku City portfolio CI
Frequently asked questions about Lamictal TM
What is Lamictal TM?
How does Lamictal TM work?
What is Lamictal TM used for?
Who makes Lamictal TM?
What drug class is Lamictal TM in?
What development phase is Lamictal TM in?
What are the side effects of Lamictal TM?
What does Lamictal TM target?
Related
- Drug class: All Anticonvulsant / Mood stabilizer drugs
- Target: All drugs targeting Voltage-gated sodium channels; glutamate release inhibition
- Manufacturer: Central Mental Clinic for Outpatients of Baku City — full pipeline
- Therapeutic area: All drugs in Neurology / Psychiatry
- Indication: Drugs for Epilepsy (partial seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome)
- Indication: Drugs for Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing